GSTP1 as a target in advanced prostate cancer
Official title: Delineate the Role of GSTP1 in Advanced Prostate Cancer
Funded at University of California Los Angeles · NIH-11330223 · Data updated 2026-11-12
This grant explores whether blocking GSTP1 can slow or stop growth of advanced, treatment-resistant prostate cancer and improve how well other therapies work.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | July 14, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $461,078 |
| NIH project number | 5R01CA274978-04 |
| Project ID | NIH-11330223 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are men with advanced or metastatic prostate cancer, especially those whose disease is resistant to hormone therapy.
✕Less likely to help
Patients with early-stage prostate cancer or cancers not driven by GSTP1 may not benefit.
What this research studies
If you or a loved one has advanced prostate cancer, this project tests how GSTP1 might drive aggressive disease and whether inhibiting GSTP1, alone or with cisplatin, could slow tumor growth in models that mimic patient tumors. Researchers will use patient-derived tumor samples and animal models to understand how GSTP1 works and to identify combinations that could be more effective than current hormone therapies. The work aims to uncover new therapeutic strategies that could be translated into clinical trials for men with resistant disease. Progress could inform future treatments that extend survival and limit disease progression.
Why it matters
Potential benefit: It could lead to new therapies that target GSTP1 and potentially improve outcomes for men with advanced, hormone-resistant prostate cancer.
How similar studies have gone: Previous work shows GSTP1 is upregulated in treatment-resistant prostate cancer and that inhibiting GSTP1 can suppress growth in models, suggesting potential benefit though clinical success awaits.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Stoyanova, Tanya I — University of California Los Angeles
- Study coordinator: Stoyanova, Tanya I
Related research
Other NIH-funded projects on the same topics.
-
Drug that blocks tumor-made male hormones and the androgen receptor for advanced prostate cancer
A new medicine aims to block both the androgen receptor and the tumor’s own production of male hormones to help men with advanced, treatment‑resistant prostate cancer.
-
Boosting a tumor-suppressing enzyme to fight advanced prostate cancer
A research grant aims to develop new molecules that enhance the PP2A enzyme to slow or stop progression of advanced prostate cancer.
-
Modulating Androgen Signals to Boost CAR T Therapy for Prostate Cancer
A new approach uses CAR T cells targeting STEAP1 to treat advanced prostate cancer, with a focus on how androgen signals affect treatment effectiveness.
-
Genomic clues to guide therapy in advanced prostate cancer
This grant looks at how a patient’s tumor and germline DNA could predict which targeted or immune therapies will work best for advanced prostate cancer.
-
DACH1-based test to predict therapy response in advanced prostate cancer
A new test using DACH1 and other markers on prostate cancer tissue aims to predict which patients will respond to therapy and guide clinical trials.
-
Understanding how doctors choose treatments to improve advanced prostate cancer care
A clinician-researcher at Duke is exploring how medical decisions are made in advanced prostate cancer to help patients get better, fairer care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.